RhAPPcast

Rheumatology Advanced Practice Providers (RhAPP)
  • 5.0 (5)
  • Medicine

This is the official podcast of Rheumatology Advanced Practice Providers (RhAPP), a non-profit 501c3 organization dedicated to developing educational programs, providing professional advancement services, and assembling resources for—and guided by—advanced practice providers (APPs).    Through our peer-to-peer network, we seek to support the integral role APPs play in the rheumatology healthcare community by providing the most relevant and timely information and communication for the treatment of their patients with rheumatic diseases. 

  1. 1d ago

    Journal Club: Efficacy & Safety of Nanoencapsulated Sirolimus Plus Pegadricase

    In this RhAPP journal club video module, Danielle Gatti-Palumbo, PharmD reviews the efficacy and safety of nanoencapsulated sirolimus plus pegadricase (NASP) in patients with uncontrolled gout, based on findings from the randomized, placebo-controlled Phase 3 DISSOLVE I and II trials. She explains how nanoencapsulated sirolimus is designed to reduce anti-drug antibody formation and support sustained serum urate lowering with pegadricase, addressing a key challenge in uricase-based gout treatment. This episode examines the study design, every-four-week dosing regimen, serum urate response, tophus resolution, tender joint counts, and health-related quality of life. Danielle discusses improved serum urate control compared with placebo, along with key safety considerations, including gout flares, stomatitis, infusion-related reactions, and anaphylaxis. She also evaluates the study’s strengths and limitations, including the 24-week analysis period and the absence of a direct comparison with pegloticase plus methotrexate. Designed for rheumatology advanced practice providers, nurse practitioners, physician assistants, pharmacists, and clinicians caring for patients with uncontrolled or tophaceous gout, this journal club provides a practical overview of an investigational urate-lowering therapy, its potential benefits, and important considerations when interpreting the clinical trial results. For more rheumatology education and clinical resources, visit RhAPP’s website, the RhAPP content rheum, or the RhAPP ACE app.

  2. 6d ago

    FAQ: What Is the Total Improvement Score and How Should It Be Interpreted in IIM Clinical Trials?

    In this RhAPP FAQ video module, Jennifer Mylod, nurse practitioner at Arizona Arthritis and Rheumatology Associates in Phoenix, Arizona, explains the Total Improvement Score, or TIS, and how it is used to assess treatment response in idiopathic inflammatory myopathies, including myositis and related autoimmune muscle diseases. This episode reviews how the ACR/EULAR Total Improvement Score serves as a composite outcome measure in inflammatory myopathy clinical trials and clinical practice by evaluating multiple disease domains, including muscle strength, physician global assessment, patient global assessment, physical function, muscle enzyme levels, and extramuscular disease activity affecting areas such as the lungs, skin, and joints. Jennifer discusses how TIS scores are interpreted, with more than 20 points indicating minimal improvement, more than 40 points indicating moderate improvement, and more than 60 points indicating major improvement. Designed for rheumatology advanced practice providers, nurse practitioners, physician assistants, and clinicians caring for patients with inflammatory muscle disease, this FAQ highlights why TIS is valuable for measuring meaningful global response, tracking disease progression, and looking beyond CK levels or muscle strength alone. For more rheumatology education and clinical resources, visit RhAPP's website, the RhAPP content rheum, or the RhAPP ACE app.

  3. Sep 3

    FAQ: What Is the Role of Autoantibodies in Disease Progression and Treatment Response in IIM?

    In this RhAPP FAQ video module, Jennifer Mylod, nurse practitioner at Arizona Arthritis and Rheumatology Associates in Phoenix, Arizona, discusses how autoantibodies help guide diagnosis, prognosis, disease monitoring, and treatment decisions in idiopathic inflammatory myopathies, including myositis, dermatomyositis, antisynthetase syndrome, and immune-mediated necrotizing myopathy. This episode highlights key myositis-specific and myositis-associated antibodies, including anti-MDA5, anti-TIF1-gamma, anti-Jo-1, anti-HMGCR, anti-SRP, and anti-Mi-2, and explains how these antibody profiles can help predict organ involvement, cancer risk, interstitial lung disease, disease severity, and expected treatment response. Designed for rheumatology advanced practice providers, nurse practitioners, physician assistants, and clinicians caring for patients with autoimmune muscle disease, this FAQ offers practical insight into using antibody testing to personalize care and monitor disease progression in inflammatory myopathies. For more rheumatology education and clinical resources, visit RhAPP’s website, the RhAPP content rheum, or the RhAPP ACE app.

  4. Sep 1

    RhAPPcast: The True Cost of Gout: Work, Wellness, and Daily Life

    In this episode of RhAPPcast, the official podcast of Rheumatology Advanced Practice Providers, host Amanda Mixon, president of RhAPP, is joined by RhAPP board member Kyle George to explore The True Cost of Gout: Work, Wellness, and Daily Life. The discussion examines how uncontrolled gout extends beyond painful flares and swollen joints, affecting mobility, employment, productivity, independence, emotional well-being, relationships, family activities, and overall quality of life. Amanda and Kyle also address the often-overlooked burden placed on spouses, family members, and caregivers, along with the broader health concerns associated with hyperuricemia, including chronic kidney disease, cardiovascular disease, and diabetes. Clinicians will gain practical insights into gout management, patient education, medication adherence, flare prophylaxis, regular uric acid monitoring, and a treat-to-target approach aimed at maintaining uric acid below 6. The episode highlights the importance of setting clear treatment expectations, reinforcing the care plan at each visit, and helping patients understand that effective long-term gout control can reduce flares and restore daily function. Explore more rheumatology podcasts, clinical education, conference content, and resources through the RhAPP Content Rheum and the RhAPP ACE 2.0 mobile app.

  5. Aug 27

    FAQ: What Are Key Diagnostic Considerations and Limitations of Antibody Testing in IIM?

    In this FAQ video module, Jennifer Mylod, nurse practitioner with Arizona Arthritis Rheumatology Associates in Phoenix, Arizona, discusses key diagnostic considerations and limitations of antibody testing in idiopathic inflammatory myopathies, including myositis, dermatomyositis, and other inflammatory muscle diseases. While myositis antibody panels can provide valuable information for diagnosis, prognosis, and disease classification, antibody testing has important limitations that clinicians must recognize. A negative myositis panel does not rule out inflammatory myopathy, as some patients may be seronegative, and false-positive results or variability between commercial laboratory assays can complicate interpretation. This educational review emphasizes that antibody results should never be interpreted in isolation, but instead should be evaluated alongside the patient’s clinical presentation, CK levels, MRI findings, EMG results, and muscle or skin biopsy findings. Jennifer also highlights that not all antibody panels include every known myositis-specific or myositis-associated antibody, making clinical judgment essential when evaluating suspected idiopathic inflammatory myopathy. Designed for rheumatology advanced practice providers, nurse practitioners, physician assistants, and clinicians caring for patients with autoimmune muscle disease, this FAQ provides practical guidance for improving diagnostic accuracy and understanding the role of antibody testing in myositis care. For more rheumatology education and clinical resources, visit RhAPP’s website, the RhAPP content rheum, or the RhAPP ACE app.

  6. Aug 18

    Journal Club Review: Deucravacitinib in Active PsA: 52-Week Efficacy and Safety From POETYK PsA-2

    In this RhAPP journal club video module, Danielle Gatti Palumbo, PharmD, reviews the Phase 3 POETYK PsA-2 clinical trial evaluating deucravacitinib in adults with active psoriatic arthritis. Deucravacitinib is an oral, selective tyrosine kinase 2, or TYK2, inhibitor that targets signaling pathways involved in psoriatic arthritis, including interleukin-23 and type I interferons. This randomized, double-blind, placebo-controlled study assessed the efficacy and safety of deucravacitinib through 52 weeks in patients who were biologic-naive or had previously received conventional disease-modifying antirheumatic drugs or TNF inhibitors. This episode reviews the POETYK PsA-2 trial design, patient population, primary and secondary endpoints, and key clinical findings. It examines improvements in ACR20, ACR50, and ACR70 responses, as well as skin symptoms, physical function, minimal disease activity, dactylitis, and enthesitis. Danielle also discusses the sustained response observed through week 52, outcomes among patients who crossed over from placebo to deucravacitinib, and the treatment’s safety profile, including common adverse events and findings related to serious infections, malignancy, major cardiovascular events, and venous thromboembolism. Designed for rheumatology advanced practice providers, pharmacists, nurse practitioners, physician assistants, and other clinicians caring for patients with psoriatic arthritis, this journal club highlights the potential role of selective TYK2 inhibition as an oral treatment option across multiple psoriatic arthritis disease domains. For more rheumatology education and clinical resources, visit RhAPP's website, the RhAPP content rheum, or the RhAPP ACE app.

  7. Aug 13

    RhAPPcast: Cracking the Code: A Rheum Derm Neuro Multispecialty Case Approach to Myositis

    In this episode of RhAPPcast, the official podcast of Rheumatology Advanced Practice Providers, host Amanda Mixon leads a multidisciplinary, case-based discussion titled “Cracking the Code: A Rheum-Derm-Neuro Multispecialty Case Approach to Myositis.” Joined by dermatology clinician Laura Bush and neuromuscular medicine PA Maggie Naclerio, this episode explores the complex and often subtle presentations of myositis, idiopathic inflammatory myopathies, dermatomyositis, immune-mediated necrotizing myopathy, and inclusion body myositis. Through real-world clinical cases, the conversation highlights how patients may first present with skin findings, proximal muscle weakness, falls, elevated CK levels, hoarseness, interstitial lung disease concerns, or atypical symptoms that can delay diagnosis. Listeners will gain practical insight into recognizing key myositis signs such as Gottron’s papules, heliotrope rash, shawl sign, holster sign, nailfold capillary changes, limb-girdle weakness, and functional decline, while also learning how dermatology, rheumatology, neurology, primary care, and pulmonology can collaborate to improve outcomes. The episode also covers important diagnostic tools and clinical pearls, including myositis antibody panels, CK trending, aldolase, ESR, CRP, thyroid testing, EMG, MRI, muscle biopsy, HMGCR antibodies, MDA5-associated disease, malignancy risk, false-positive antibody testing, and the importance of a high-quality physical exam. Designed for rheumatology APPs, physician assistants, nurse practitioners, dermatology clinicians, neurology providers, and all healthcare professionals caring for patients with autoimmune muscle disease, this episode emphasizes earlier recognition, better specialty coordination, and individualized treatment strategies for patients living with myositis. Subscribe to RhAPPcast for more rheumatology education, clinical insights, and practical updates from the RhAPP community.

  8. Aug 12

    RhAPPcast: Beyond the Joint: Uncontrolled Gout as a Systemic Disease

    In this episode of RhAPPcast, the official podcast of Rheumatology Advanced Practice Providers, host Amanda Mixon is joined by RhAPP board member Wendy Simmons to explore uncontrolled gout as a systemic inflammatory disease with effects that extend far beyond acute joint pain. The discussion examines how persistent hyperuricemia can lead to monosodium urate crystal deposition, ongoing inflammation, tophi, bone erosion, cartilage damage, tendon complications, and progressive musculoskeletal impairment. Amanda and Wendy also review the connection between uncontrolled gout and common comorbidities, including cardiovascular disease, chronic kidney disease, hypertension, diabetes, obesity, atrial fibrillation, and heart failure. Listeners will gain practical insights into recognizing silent gout progression, assessing uric acid levels and organ function, identifying patients at risk for long-term systemic complications, and coordinating care across rheumatology, primary care, cardiology, and nephrology. The episode also highlights the importance of regular follow-up, patient education, treat-to-target strategies, and individualized gout management. For more rheumatology podcasts, clinical updates, and educational resources designed for advanced practice providers, visit the RhAPP Content Rheum or access education through the RhAPP ACE mobile app.

See All (214)

Ratings & Reviews

5
out of 5
5 Ratings

About

This is the official podcast of Rheumatology Advanced Practice Providers (RhAPP), a non-profit 501c3 organization dedicated to developing educational programs, providing professional advancement services, and assembling resources for—and guided by—advanced practice providers (APPs).    Through our peer-to-peer network, we seek to support the integral role APPs play in the rheumatology healthcare community by providing the most relevant and timely information and communication for the treatment of their patients with rheumatic diseases. 

Information

  • Creator
    Rheumatology Advanced Practice Providers (RhAPP)
  • Years Active
    2023 - 2026
  • Episodes
    214
  • Rating
    Clean
  • Copyright
    © 2025 RhAPPcast
  • Show Website
    RhAPPcast

You Might Also Like